Management of Metastatic Breast Cancer with Choroidal Metastasis
For hormone receptor-positive (HR+/HER2-) metastatic breast cancer with choroidal metastasis, initiate systemic therapy with a CDK4/6 inhibitor plus endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment, which can achieve regression of choroidal lesions without immediate radiation. For triple-negative or HER2-positive disease, proceed with appropriate systemic therapy per subtype, reserving external beam radiotherapy (EBR) for symptomatic lesions or those threatening vision.
Initial Diagnostic Approach
When a patient with metastatic breast cancer presents with visual symptoms:
- Confirm choroidal metastasis through dilated fundus examination and optical coherence tomography 1
- Re-biopsy accessible metastatic sites (avoid bone if possible) to reassess ER, PR, and HER2 status, as receptor status can change from primary tumor 2
- Assess disease burden across all sites, as choroidal metastasis typically indicates widespread systemic disease 3
The median survival after diagnosis of choroidal metastasis is approximately 8 months (range 1-34 months), emphasizing the importance of systemic disease control 3.
Treatment Algorithm by Breast Cancer Subtype
HR-Positive/HER2-Negative Disease (Most Common)
First-line systemic therapy alone is appropriate for most patients:
- CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) plus aromatase inhibitor or fulvestrant 4, 5, 6
- This approach achieves choroidal tumor regression in documented cases, avoiding immediate radiation and its complications 6
- One case report demonstrated complete regression of choroidal metastasis with palbociclib as first-line palliative therapy 6
- Another case showed sustained response for at least 6 months with CDK4/6 inhibitor plus fulvestrant 5
Reserve EBR for:
- Vision-threatening lesions requiring urgent intervention
- Failure of systemic therapy to control ocular disease
- Symptomatic lesions causing significant visual impairment
Triple-Negative Breast Cancer
- Chemotherapy with or without immune checkpoint inhibitor based on PD-L1 status 2
- Consider earlier EBR given typically more aggressive biology and less predictable response to systemic therapy
HER2-Positive Disease
- Anti-HER2 therapy plus chemotherapy per standard metastatic protocols 2
- Systemic therapy may control choroidal disease, but monitor closely for response
Radiation Therapy Considerations
While EBR has historically been considered the gold standard for choroidal metastasis 4, 1, the evidence supports a more nuanced approach:
- EBR achieves local tumor control in 20/23 eyes (87%) with good visual outcomes (mean final visual acuity logMAR 0.11) 3
- Systemic therapy alone also achieves comparable visual outcomes (mean final visual acuity logMAR 0.18, p=0.48 vs. EBR) 3
- Delaying EBR allows assessment of systemic therapy response and avoids radiation-related complications (radiation retinopathy, optic neuropathy, cataract) 4
Critical Pitfalls to Avoid
Do not assume receptor status matches the primary tumor - up to 20-30% of cases show discordance requiring treatment modification 2
Do not reflexively radiate all choroidal metastases - HR-positive disease often responds to systemic therapy, allowing radiation deferral 4, 6
Do not neglect ophthalmologic evaluation in patients with advanced breast cancer and visual symptoms - early detection improves outcomes 5
Do not perform surgery on choroidal lesions with concurrent complications (e.g., retinal detachment) without careful risk-benefit analysis and multidisciplinary discussion 1
Monitoring and Follow-up
- Serial ophthalmologic examinations every 4-8 weeks initially to assess response
- Systemic imaging to evaluate overall disease burden and response
- Switch to EBR if progression of choroidal lesions despite systemic therapy or if vision-threatening complications develop
The key paradigm shift is recognizing that choroidal metastasis should be managed primarily as systemic disease, with local therapy reserved for specific indications rather than as automatic first-line treatment, particularly in HR-positive disease 4, 3, 6.